Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Abstract

INTRODUCTION Vemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF(V600E) melanoma treated in the phase 1 vemurafenib trial is reported. METHODS Patients received vemurafenib 240-1120 mg (dose escalation cohort) or 960 mg… (More)
DOI: 10.1016/j.ejca.2015.04.010

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Statistics

02040201520162017
Citations per Year

Citation Velocity: 12

Averaging 12 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.